Authors' reply to "Outcomes for metastatic triple-negative breast cancer patients treated with sacituzumab govitecan in clinical studies and real-world studies: a single-arm meta-analysis".
APA
Liang S, Liao W, et al. (2026). Authors' reply to "Outcomes for metastatic triple-negative breast cancer patients treated with sacituzumab govitecan in clinical studies and real-world studies: a single-arm meta-analysis".. European journal of clinical pharmacology, 82(4). https://doi.org/10.1007/s00228-026-04038-2
MLA
Liang S, et al.. "Authors' reply to "Outcomes for metastatic triple-negative breast cancer patients treated with sacituzumab govitecan in clinical studies and real-world studies: a single-arm meta-analysis".." European journal of clinical pharmacology, vol. 82, no. 4, 2026.
PMID
41920310
같은 제1저자의 인용 많은 논문 (5)
- Outcomes for metastatic triple-negative breast cancer patients treated with sacituzumab govitecan in clinical studies and real-world studies: a single-arm meta-analysis.
- A tumor-derived mitochondrial tsRNA drives vascular invasion of lung adenocarcinoma by promoting ribosomal assembly in endothelial cells.
- A streamlined technique for in-depth ubiquitomics analysis of formalin-fixed paraffin-embedded tissues.
- Rhein/Fe nanoassembly for triple-negative breast cancer treatment via a ferroptosis and immunogenic death.
- A mechanistic study revealing that SLCO1B3 promotes gastric cancer development and metastasis through MAP1S expression downregulation.